<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/76EDEF55-C6B3-41B8-967E-AAAE9C2BD373"><gtr:id>76EDEF55-C6B3-41B8-967E-AAAE9C2BD373</gtr:id><gtr:name>Chemocentryx</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Immunity and Infection</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/76EDEF55-C6B3-41B8-967E-AAAE9C2BD373"><gtr:id>76EDEF55-C6B3-41B8-967E-AAAE9C2BD373</gtr:id><gtr:name>Chemocentryx</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/29FD8816-262E-4BC7-83C4-73B09EA3158D"><gtr:id>29FD8816-262E-4BC7-83C4-73B09EA3158D</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:surname>Parker</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1100448"><gtr:id>14796959-0A0F-48BD-A361-A56A329190CC</gtr:id><gtr:title>Role of CXCR6/CXCL16 in steatohepatitis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1100448</gtr:grantReference><gtr:abstractText>Liver disease is a significant health problem in the UK where rates of liver disease are rising as a consequence of hepatitis C infection, rising rates of alcoholic liver disease (ALD) and a high prevalence of non-alcoholic fatty liver disease (NALFD) a liver disease related to obesity, diabetes and high blood pressure. Despite their different causes most chronic liver diseases arise as a consequence of an inflammatory response to liver injury that causes scarring and destruction of the liver leading to liver failure. The inflammation in the liver is due to white blood cells leaving the bloodstream and entering liver tissue where they can orchestrate liver damage. This process is controlled by numerous molecules in the liver and on white cells that promote their entry and retention in the liver. 
We propose to focus our research on one of these molecules, a chemokine called CXCL16 and its corresponding receptor on white cells, CXCR6. We have already shown that CXCR6 is concentrated on white cells that cause liver damage and I will now determine precisely what this receptor does and by using recently developed specific inhibitors of CXCR6, elucidate the inflammatory process and investigate new means of treating it.</gtr:abstractText><gtr:technicalSummary>Aim: The chemokine receptor CXCR6 is expressed by specific subsets of effector lymphocytes that we have shown to be present within the inflamed liver. The present project will define the role of CXCR6 and its chemokine ligand CXCL16 in the pathogenesis of hepatitis and liver injury with the object of defining CXCR6 as a therapeutic target in liver disease. 
Objectives: To define
i. CXCL16 expression on parenchymal and non-parenchymal cells in normal and diseased liver
ii. The functional lymphocyte subsets that express CXCR6 in the inflamed liver
iii. The role of CXCR6/CXCL16 in lymphocyte recruitment to and positioning within the liver
iv. The effect of manipulating CXCL16/CXCR6 in murine models of liver inflammation 
Design and Methodology: 
1) Human studies: lymphocytes, parenchymal and non-parenchymal cells will be isolated from livers removed at transplantation in our Unit allowing me to define a) expression patterns of CXCL16 and CXCR6 in normal and diseased liver using immunohistochemistry, flow cytometry and qRT-PCR b) functional lymphocyte subsets that express CXCR6 using flow cytometry and intracellular cytokine staining c) the function of CXCR6/CXCL16 in the recruitment of lymphocytes using flow-based adhesion assays incorporating human hepatic endothelium and stellate cells to model the hepatic sinusoid in vitro d) the effect of CXCR6/CXCL16 interactions on the activation, survival and cytokine secretion of interacting lymphocytes and epithelial cells. 
2) Murine models of liver inflammation: models established in our laboratory will be used to determine the effect of inhibiting CXCR6 in vivo using blocking antibodies, small molecule inhibitors and genetically modified mice to define the role of CXCR6 in liver inflammation in vivo. 
3) Development of therapeutic CXCR6 inhibitors: I will spend time at Chemocentryx Inc in Paolo Alto testing the potential of novel small molecule inhibitors to block CXCR6 dependent responses and then apply the inhibitors to the in vitro and in vivo models available in Birmingham.
Scientific opportunities/Medical opportunities
The project will provide a superb training in cellular immunology within the Centre for Liver Research and the MRC Centre for Immune Regulation. I will participate in the development of novel CXCR6 antagonists during my stay at Chemocentryx, a SME who lead the world in the development of chemokine receptor antagonists. The information I generate will potentially lead to proof of concept clinical trials in liver disease using CXCR6 inhibitors within 5 years.</gtr:technicalSummary><gtr:fund><gtr:end>2015-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>223064</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>ChemoCentryx</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>ChemoCentryx collaboration</gtr:description><gtr:id>2A39A3ED-3767-439F-97B2-40DCB84AA5FD</gtr:id><gtr:impact>Abstracts at EASL 2014 and submitted for EASL 2015</gtr:impact><gtr:outcomeId>5450cb2e18a163.39046500-1</gtr:outcomeId><gtr:partnerContribution>Financial cost of trips to US. Providing reagents, mice and new drugs</gtr:partnerContribution><gtr:piContribution>Ongoing collaboration with ChemoCentryx after first visit in 2013, to pursue research into role of CCR2 in fatty liver disease with view to potential therapy</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Acute liver failure research</gtr:description><gtr:id>A58AE8DB-11E2-4DC8-A24D-91679C842F72</gtr:id><gtr:impact>Abstract submitted to EASL 2015</gtr:impact><gtr:outcomeId>5450cbd23ba679.70059475-1</gtr:outcomeId><gtr:partnerContribution>Investigations in ex vivo human samples</gtr:partnerContribution><gtr:piContribution>Investigation of role of CCR9 expressed by monocytes/macrophages in acute liver failure</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Acute liver failure research</gtr:description><gtr:id>40E9CA80-806F-45A6-8885-2DBA7C36DBC4</gtr:id><gtr:impact>Abstract submitted to EASL 2015</gtr:impact><gtr:outcomeId>5450cbd23ba679.70059475-2</gtr:outcomeId><gtr:partnerContribution>Investigations in ex vivo human samples</gtr:partnerContribution><gtr:piContribution>Investigation of role of CCR9 expressed by monocytes/macrophages in acute liver failure</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Public and Patient Involvement Committee</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>923CE9D6-C858-438C-9643-57E679C974DD</gtr:id><gtr:impact>Attended local PPI group to present proposed research projects for discussion

Discussion regarding design of trials with PPI group</gtr:impact><gtr:outcomeId>5450ca5f812282.64986831</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Centre for Liver Research public engagement</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>3FEAC123-B81A-4D94-B7DC-73D545CE02F3</gtr:id><gtr:impact>Taking part in research fair held at Queen Elizabeth Hospital Birmingham for patients and public

The Centre for Liver Research was awarded best stand</gtr:impact><gtr:outcomeId>5450c79cb51898.42727120</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Sheila Sherlock Physician Scientist Fellowship</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>European Association for the Study of the Liver (EASL)</gtr:fundingOrg><gtr:id>869E055F-1113-4606-9BA9-8867576A2E18</gtr:id><gtr:outcomeId>5450c70873b379.61077578</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Sheila Sherlock Travelling Fellowship in Hepatology</gtr:description><gtr:end>2014-08-02</gtr:end><gtr:fundingOrg>Royal College of Physicians of London</gtr:fundingOrg><gtr:id>59E4BCA2-FAD0-412D-9544-EE7DBE9D9661</gtr:id><gtr:outcomeId>5450c6c47b2f71.83641381</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>DBDCA4BD-E187-4534-8EF9-D44684DBEB60</gtr:id><gtr:title>Transplanting Patients with Alcohol-related Liver Disease in the National Health System: New Rules and Decisions.</gtr:title><gtr:parentPublicationTitle>Alcohol and alcoholism (Oxford, Oxfordshire)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3a10de934ad1c877b9ea72dcb014fb4"><gtr:id>f3a10de934ad1c877b9ea72dcb014fb4</gtr:id><gtr:otherNames>Parker R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0735-0414</gtr:issn><gtr:outcomeId>5a9fb2775e7e95.39281126</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37D14A2F-75CC-40CB-A346-458BE25A2509</gtr:id><gtr:title>Role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension.</gtr:title><gtr:parentPublicationTitle>Clinics in liver disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3a10de934ad1c877b9ea72dcb014fb4"><gtr:id>f3a10de934ad1c877b9ea72dcb014fb4</gtr:id><gtr:otherNames>Parker R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1089-3261</gtr:issn><gtr:outcomeId>pm_540e17be17b20a4b6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5855B45F-2906-44F1-B211-DA4EF593A3F5</gtr:id><gtr:title>Informed consent in surveillance for hepatocellular carcinoma in patients with cirrhosis.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68859e2678f8b3f51bdc173b90573c7b"><gtr:id>68859e2678f8b3f51bdc173b90573c7b</gtr:id><gtr:otherNames>Rowe IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>5450c9161f3000.35335155</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F1021FE-BB85-428E-819E-D0ADC6C13204</gtr:id><gtr:title>Systematic review: Current evidence in non-alcoholic fatty liver disease lacks relevance to patients with advanced fibrosis.</gtr:title><gtr:parentPublicationTitle>Journal of gastroenterology and hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3a10de934ad1c877b9ea72dcb014fb4"><gtr:id>f3a10de934ad1c877b9ea72dcb014fb4</gtr:id><gtr:otherNames>Parker R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0815-9319</gtr:issn><gtr:outcomeId>5a9fb1bd86fd09.51772532</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC1C4006-1ED0-4D7B-A8F8-0CE67DCA193F</gtr:id><gtr:title>Alcohol and substance abuse in solid-organ transplant recipients.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3a10de934ad1c877b9ea72dcb014fb4"><gtr:id>f3a10de934ad1c877b9ea72dcb014fb4</gtr:id><gtr:otherNames>Parker R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn><gtr:outcomeId>pm_15002_22_24025323</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B082FDF-10FB-4C04-AFCE-DFE39759C964</gtr:id><gtr:title>Patient and public attitudes regarding selection for liver transplantation.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3a10de934ad1c877b9ea72dcb014fb4"><gtr:id>f3a10de934ad1c877b9ea72dcb014fb4</gtr:id><gtr:otherNames>Parker R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn><gtr:outcomeId>5450c94c0873e7.59035667</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08CDE04D-8711-487C-9C78-C330685316E6</gtr:id><gtr:title>Paracrine signals from liver sinusoidal endothelium regulate hepatitis C virus replication.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68859e2678f8b3f51bdc173b90573c7b"><gtr:id>68859e2678f8b3f51bdc173b90573c7b</gtr:id><gtr:otherNames>Rowe IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>pm_15002_22_23775568</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38C6CB49-12F9-4A13-8EC1-31B8CD60241F</gtr:id><gtr:title>Assessment of the quality of evidence underlying international guidelines in liver disease.</gtr:title><gtr:parentPublicationTitle>The American journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68859e2678f8b3f51bdc173b90573c7b"><gtr:id>68859e2678f8b3f51bdc173b90573c7b</gtr:id><gtr:otherNames>Rowe IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0002-9270</gtr:issn><gtr:outcomeId>pm_15002_22_22951868</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6517C132-57A4-4DC1-B933-7E5E5A5406DE</gtr:id><gtr:title>Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis.</gtr:title><gtr:parentPublicationTitle>Alimentary pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3a10de934ad1c877b9ea72dcb014fb4"><gtr:id>f3a10de934ad1c877b9ea72dcb014fb4</gtr:id><gtr:otherNames>Parker R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-2813</gtr:issn><gtr:outcomeId>pm_15002_22_23489011</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>240B2DE8-492A-48B6-A1A5-9D924C09322D</gtr:id><gtr:title>Alcoholic hepatitis: calling time on an unhelpful diagnosis.</gtr:title><gtr:parentPublicationTitle>The lancet. Gastroenterology &amp; hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3a10de934ad1c877b9ea72dcb014fb4"><gtr:id>f3a10de934ad1c877b9ea72dcb014fb4</gtr:id><gtr:otherNames>Parker R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a9fb277d18ae2.14066513</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77DB98E7-E2A6-484F-98A8-CEF014D033D4</gtr:id><gtr:title>Management of patients with difficult autoimmune hepatitis.</gtr:title><gtr:parentPublicationTitle>Therapeutic advances in gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3a10de934ad1c877b9ea72dcb014fb4"><gtr:id>f3a10de934ad1c877b9ea72dcb014fb4</gtr:id><gtr:otherNames>Parker R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1756-283X</gtr:issn><gtr:outcomeId>broyTvfoaut</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>441EA011-6E6D-450B-B509-D6BBA801F5B4</gtr:id><gtr:title>Mental health disorders and solid-organ transplant recipients.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c5f1cbfeb68c0c0b3d5893609fc99a7"><gtr:id>7c5f1cbfeb68c0c0b3d5893609fc99a7</gtr:id><gtr:otherNames>Corbett C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn><gtr:outcomeId>pm_15002_22_23743726</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BFFEEB0-78A4-4CB3-ADC6-B6FB85A86A61</gtr:id><gtr:title>Estimated short-term mortality following TIPS insertion for patients with hepatic hydrothorax.</gtr:title><gtr:parentPublicationTitle>The American journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3a10de934ad1c877b9ea72dcb014fb4"><gtr:id>f3a10de934ad1c877b9ea72dcb014fb4</gtr:id><gtr:otherNames>Parker R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0002-9270</gtr:issn><gtr:outcomeId>5450c94ba789a1.34799947</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0920D01F-D479-45DF-AB57-53711D2D47DE</gtr:id><gtr:title>A novel scoring system to guide risk assessment of Wernicke's encephalopathy.</gtr:title><gtr:parentPublicationTitle>Alcoholism, clinical and experimental research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e4e5e248878a874673b0e17efd75d4d0"><gtr:id>e4e5e248878a874673b0e17efd75d4d0</gtr:id><gtr:otherNames>Green A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0145-6008</gtr:issn><gtr:outcomeId>nJMj4Z5vgXq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DEA2BEA-908C-4B45-9039-563B26995763</gtr:id><gtr:title>Operator training requirements and diagnostic accuracy of Fibroscan in routine clinical practice.</gtr:title><gtr:parentPublicationTitle>Postgraduate medical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3d1f365e7f237e849abd7b8a60e266e"><gtr:id>d3d1f365e7f237e849abd7b8a60e266e</gtr:id><gtr:otherNames>Armstrong MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0032-5473</gtr:issn><gtr:outcomeId>pm_15002_22_23924687</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40814362-A597-45B6-AFF5-06AC04A0BFDA</gtr:id><gtr:title>Reticulocyte count and hemoglobin concentration predict survival in candidates for liver transplantation.</gtr:title><gtr:parentPublicationTitle>Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3a10de934ad1c877b9ea72dcb014fb4"><gtr:id>f3a10de934ad1c877b9ea72dcb014fb4</gtr:id><gtr:otherNames>Parker R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0041-1337</gtr:issn><gtr:outcomeId>5450c9a19bd565.45561421</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>807690CC-B418-4809-8019-BEC05AD2F85D</gtr:id><gtr:title>Alcohol, adipose tissue and liver disease: mechanistic links and clinical considerations.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Gastroenterology &amp; hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3a10de934ad1c877b9ea72dcb014fb4"><gtr:id>f3a10de934ad1c877b9ea72dcb014fb4</gtr:id><gtr:otherNames>Parker R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1759-5045</gtr:issn><gtr:outcomeId>5a9fb277a43734.22091212</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BBDF727E-E48A-470A-B2C3-FAFBD9257ECB</gtr:id><gtr:title>Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3d1f365e7f237e849abd7b8a60e266e"><gtr:id>d3d1f365e7f237e849abd7b8a60e266e</gtr:id><gtr:otherNames>Armstrong MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>5450c9a1cb0645.50139065</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1271BA1-5295-4457-BC97-20A707B0CF30</gtr:id><gtr:title>Survival from alcoholic hepatitis has not improved over time.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08d31d2922cc1da20376c184004574a3"><gtr:id>08d31d2922cc1da20376c184004574a3</gtr:id><gtr:otherNames>Hughes E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5a9fb1bd5ab153.33401324</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>988B0F9D-89D4-4219-B3D7-577A92F97125</gtr:id><gtr:title>CC Chemokine Receptor 2 Promotes Recruitment of Myeloid Cells Associated with Insulin Resistance in Non-Alcoholic Fatty Liver Disease.</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Gastrointestinal and liver physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3a10de934ad1c877b9ea72dcb014fb4"><gtr:id>f3a10de934ad1c877b9ea72dcb014fb4</gtr:id><gtr:otherNames>Parker R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0193-1857</gtr:issn><gtr:outcomeId>5a9fb1bd1600c0.72743136</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88BEF026-939A-49A8-A908-02D31AA3F3B3</gtr:id><gtr:title>Clinical and microbiological features of infection in alcoholic hepatitis: an international cohort study.</gtr:title><gtr:parentPublicationTitle>Journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3a10de934ad1c877b9ea72dcb014fb4"><gtr:id>f3a10de934ad1c877b9ea72dcb014fb4</gtr:id><gtr:otherNames>Parker R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0944-1174</gtr:issn><gtr:outcomeId>5a2fd79e06b3f3.62737183</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0124CC2C-8B3F-486B-B513-42E7442FAACD</gtr:id><gtr:title>Appropriateness of hepatitis a vaccination in patients with hepatitis C.</gtr:title><gtr:parentPublicationTitle>The American journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68859e2678f8b3f51bdc173b90573c7b"><gtr:id>68859e2678f8b3f51bdc173b90573c7b</gtr:id><gtr:otherNames>Rowe IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0002-9270</gtr:issn><gtr:outcomeId>pm_15002_22_22388028</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1100448</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D81A471F-556F-4570-BF6A-5D197943223C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Oral and Gastrointestinal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>